Skip to main content
. 2014 Aug 15;14:592. doi: 10.1186/1471-2407-14-592

Figure 2.

Figure 2

Individual study and comparative meta-estimate hazard ratios and odds ratios for overall survival, progression-free survival, and response for bevacizumab with interferon (Bev + IFN), sunitinib (Sun), pazopanib (Pazo), and interferon alone (IFN) as first-line therapy for patients with clear cell renal cell carcinoma.